Jyong Biotech’s Pharmaceutical Innovation Recognized with Gold at 2025 Taipei Biotech Awards

Posted on by

New Taipei City, Taiwan, Sept. 29, 2025 — Jyong Biotech Ltd. (Nasdaq: MENS), a Taiwan-based, science-focused biotechnology company, announced that its subsidiary, Health Ever Bio-Tech Co., Ltd., received the Innovation Gold Award at the 2025 Taipei Biotech Awards. The award recognizes the development of BOTRESO®, an oral, plant-derived investigational new drug for benign prostatic hyperplasia (BPH) / lower urinary tract syndrome (LUTS). Jyong Biotech specializes in creating innovative new drugs, primarily from plants, to treat urinary system diseases, initially targeting the U.S., EU, and Asian markets. The Taipei Biotech Awards are considered the “Oscars of Taiwan’s biotech industry.” Taipei City Mayor Wayne Chiang presented the Gold Award, which includes a cash prize exceeding US$26,000, during the ceremony to honor innovation and cross-disciplinary excellence in biotechnology.

(Vincent Chang, Associate Manager of Health Ever Bio-Tech Co., Ltd., accepts the 2025 Taipei Biotech Awards Innovation Gold Award on behalf of the company from Taipei City Mayor Wayne Chiang)

BOTRESO®, the award-winning product, is protected by multiple pharmaceutical composition patents worldwide and has undergone four Phase III clinical trials (API-1) in the U.S. and Taiwan. Originating in Taiwan, BOTRESO® is the first oral botanical new drug developed in Taiwan to gain U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) approval and progress to Phase III trials. The new drug candidate (API-1) has completed the IND process, and a New Drug Application (NDA) has been submitted to the U.S. FDA.

“It is a great honor to receive the 2025 Taipei Biotech Awards Innovation Gold Award. It validates the years of research and development invested in BOTRESO®,” said Fu-Feng Kuo, Chairwoman and CEO of Jyong Biotech. “This recognition underscores our leadership in plant-derived drug innovation and our dedication to providing safe and effective treatments to patients globally. We will continue to expand our global presence and deliver first-class botanical new drugs to address critical healthcare needs.”

About Jyong Biotech Ltd.

Jyong Biotech Ltd., headquartered in Taiwan, is a science-driven biotechnology company focused on developing and commercializing innovative plant-derived new drugs, primarily for treating urinary system diseases. The company is initially concentrating on the U.S., EU, and Asian markets. Since its founding in 2002, Jyong Biotech has developed integrated capabilities covering all key aspects of drug development, from early-stage discovery to commercialization, including clinical trials and regulatory affairs. Utilizing its strong R&D and proprietary platform, the company is developing several botanical drug candidates, including BOTRESO®, another clinical-stage candidate, and other preclinical candidates. Jyong Biotech aims to develop and provide innovative drugs to meet customer health needs and to be a highly respected business organization.

For more information, please visit: , .

Forward-Looking Statement

This press release includes forward-looking statements regarding plans, objectives, goals, strategies, future events, or performance, and underlying assumptions. The use of words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate,” or similar expressions indicates forward-looking statements. These statements are not guarantees of future performance and involve risks and uncertainties that could cause actual results to differ materially from expectations. These risks include, but are not limited to, market conditions and other factors described in the “Risk Factors” section of the registration statement filed with the SEC. Investors are cautioned against placing undue reliance on these forward-looking statements. Additional factors are discussed in the company’s SEC filings, available for review at . The company does not undertake any obligation to revise these statements to reflect events or circumstances after the date of this release.

For more information, please contact:
Investor Relations
WFS Investor Relations Inc.
Janice Wang
Email: 
Phone: +1 628 283 9214

“`